LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Intestinal Mucosa Fungus Can Affect Lung Health

By LabMedica International staff writers
Posted on 04 Mar 2019
Print article
Image: A diagram of how human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans (Photo courtesy of the University of Kiel).
Image: A diagram of how human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans (Photo courtesy of the University of Kiel).
The composition of the microbiome, the countless bacteria, fungi and viruses that colonize our body surface, skin, intestines or lungs, makes a decisive contribution to human health or disease. However, biological mechanisms that cause inflammations in the microbiome are still largely unknown.

Candida albicans is an opportunistic pathogenic yeast that is a common member of the human gut flora, and stimulates the immune system to produce specific defense cells, so-called Th17 cells. However, some of these Th17 cells then attack other fungi, such as Aspergillus fumigatus. This phenomenon is called cross-reactivity.

Scientists collaborating with the University of Kiel (Kiel, Germany) identified the mucocutaneous pathobiont C. albicans as the major direct inducer of human anti-fungal Th17 cells. Th17 cells directed against other fungi are induced by cross-reactivity to C. albicans. Intestinal inflammation expands total C. albicans and cross-reactive Th17 cells. Strikingly, Th17 cells cross-reactive to the airborne fungus A. fumigatus are selectively activated and expanded in patients with airway inflammation, especially during acute allergic bronchopulmonary aspergillosis.

This indicates a direct link between protective intestinal Th17 responses against C. albicans and lung inflammation caused by airborne fungi. The team identified heterologous immunity to a single, ubiquitous member of the microbiota as a central mechanism for systemic induction of human anti-fungal Th17 responses and as a potential risk factor for pulmonary inflammatory diseases.

Oliver A. Cornely, MD, FACP, FIDSA, a professor and infectious disease specialist, and co-author of the study, said, “'With this observation, we were able to show for the first time how a single member of the microbiome, Candida albicans, influences the specific immune response to a large group of other microbes. Immune cross-reactivity is probably a common mechanism by which the microbiome manipulates the immune systemwith both protective and harmful effects.” The study was published on March 7, 2019, in the journal Cell.

Related Links:
University of Kiel

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.